
|Articles|May 15, 2005
Site-active steroid provides symptomatic relief for patients with dry eye disease
Miami—Anti-inflammatory treatment using loteprednol etabonate suspension 0.2% (Alrex, Bausch & Lomb) appears to offer a safe and useful option for symptomatic relief in patients with dry eye, according to Roberto Beraja, MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: Advancements in laser refractive surgery
2
From then to next: Five decades of transformation in ophthalmology
3
Optigo: Lead anti-VEGF program advancing toward IND-enabling studies
4
Q&A: Advancing a long-acting anti-VEGF candidate: What it means for retinal disease
5


















































.png)


